1. Home
  2. VYGR vs KMDA Comparison

VYGR vs KMDA Comparison

Compare VYGR & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • KMDA
  • Stock Information
  • Founded
  • VYGR 2013
  • KMDA 1990
  • Country
  • VYGR United States
  • KMDA Israel
  • Employees
  • VYGR N/A
  • KMDA N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • KMDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • VYGR Health Care
  • KMDA Health Care
  • Exchange
  • VYGR Nasdaq
  • KMDA Nasdaq
  • Market Cap
  • VYGR 342.5M
  • KMDA 349.6M
  • IPO Year
  • VYGR 2015
  • KMDA N/A
  • Fundamental
  • Price
  • VYGR $5.22
  • KMDA $7.08
  • Analyst Decision
  • VYGR Strong Buy
  • KMDA Strong Buy
  • Analyst Count
  • VYGR 9
  • KMDA 2
  • Target Price
  • VYGR $15.53
  • KMDA $14.50
  • AVG Volume (30 Days)
  • VYGR 361.6K
  • KMDA 143.6K
  • Earning Date
  • VYGR 02-26-2025
  • KMDA 03-05-2025
  • Dividend Yield
  • VYGR N/A
  • KMDA N/A
  • EPS Growth
  • VYGR N/A
  • KMDA 124.29
  • EPS
  • VYGR 0.47
  • KMDA 0.27
  • Revenue
  • VYGR $163,784,000.00
  • KMDA $158,380,000.00
  • Revenue This Year
  • VYGR N/A
  • KMDA $15.37
  • Revenue Next Year
  • VYGR N/A
  • KMDA $8.58
  • P/E Ratio
  • VYGR $11.19
  • KMDA $25.99
  • Revenue Growth
  • VYGR 3.40
  • KMDA 4.52
  • 52 Week Low
  • VYGR $4.99
  • KMDA $4.74
  • 52 Week High
  • VYGR $10.66
  • KMDA $8.00
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 38.79
  • KMDA 66.54
  • Support Level
  • VYGR $4.99
  • KMDA $7.00
  • Resistance Level
  • VYGR $5.45
  • KMDA $7.23
  • Average True Range (ATR)
  • VYGR 0.26
  • KMDA 0.32
  • MACD
  • VYGR -0.05
  • KMDA 0.04
  • Stochastic Oscillator
  • VYGR 17.97
  • KMDA 56.81

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: